{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:13:03Z","timestamp":1787317983441,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,4,9]],"date-time":"2016-04-09T00:00:00Z","timestamp":1460160000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s15010-016-0894-y","type":"journal-article","created":{"date-parts":[[2016,4,9]],"date-time":"2016-04-09T11:52:14Z","timestamp":1460202734000},"page":"599-606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany"],"prefix":"10.1007","volume":"44","author":[{"given":"Maureen","family":"Watt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"McCrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhvinder","family":"Johal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Posnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameel","family":"Nazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,9]]},"reference":[{"key":"894_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhin.2012.02.004","volume":"81","author":"PN Wiegand","year":"2012","unstructured":"Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect. 2012;81:1\u201314.","journal-title":"J Hosp Infect"},{"key":"894_CR2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.idc.2014.11.003","volume":"29","author":"JH Kwon","year":"2015","unstructured":"Kwon JH, Olsen MA, Dubberke ER. The morbidity, mortality, and costs associated with Clostridium difficile infection. Infect Dis Clin North Am. 2015;29:123\u201334.","journal-title":"Infect Dis Clin North Am"},{"key":"894_CR3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","volume":"364","author":"TJ Louie","year":"2011","unstructured":"Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422\u201331.","journal-title":"N Engl J Med"},{"key":"894_CR4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMoa0907635","volume":"362","author":"I Lowy","year":"2010","unstructured":"Lowy I, Molrine DC, Leav BA, Blair MB, Baxter R, Gerding DN, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362:197\u2013205.","journal-title":"N Engl J Med"},{"key":"894_CR5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12064","volume":"18","author":"E Bouza","year":"2012","unstructured":"Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect. 2012;18:5\u201312.","journal-title":"Clin Microbiol Infect"},{"key":"894_CR6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2011.59","volume":"8","author":"CM Surawicz","year":"2011","unstructured":"Surawicz CM, Alexander J. Treatment of refractory and recurrent Clostridium difficile infection. Nat Rev Gastroenterol Hepatol. 2011;8:330\u20139.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"894_CR7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/cid\/cir404","volume":"53","author":"KM Mullane","year":"2011","unstructured":"Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011;53:440\u20137.","journal-title":"Clin Infect Dis"},{"key":"894_CR8","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1093\/cid\/cis356","volume":"55","author":"DW Eyre","year":"2012","unstructured":"Eyre DW, Walker AS, Wyllie D, Dingle KE, Griffiths D, Finney J, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis. 2012;55:S77\u201387.","journal-title":"Clin Infect Dis"},{"key":"894_CR9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2040622313511285","volume":"5","author":"K Mullane","year":"2014","unstructured":"Mullane K. Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance. Ther Adv Chronic Dis. 2014;5:69\u201384.","journal-title":"Ther Adv Chronic Dis."},{"key":"894_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12418","volume":"20","author":"SB Debast","year":"2014","unstructured":"Debast SB, Bauer MP, Kuijper EJ, European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20:1\u201326.","journal-title":"Clin Microbiol Infect"},{"key":"894_CR11","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.mayocp.2012.07.016","volume":"87","author":"S Khanna","year":"2012","unstructured":"Khanna S, Pardi DS. Clostridium difficile infection: new insights into management. Mayo Clin Proc. 2012;87:1106\u201317.","journal-title":"Mayo Clin Proc"},{"key":"894_CR12","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2012.45.5899","volume":"31","author":"OA Cornely","year":"2013","unstructured":"Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol. 2013;31:2493\u20139.","journal-title":"J Clin Oncol"},{"key":"894_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000351757","volume":"38","author":"KM Mullane","year":"2013","unstructured":"Mullane KM, Cornely OA, Crook DW, Golan Y, Louie TJ, Miller MA, et al. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol. 2013;38:1\u201311.","journal-title":"Am J Nephrol"},{"key":"894_CR14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jhin.2009.10.016","volume":"74","author":"SS Ghantoji","year":"2010","unstructured":"Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010;74:309\u201318.","journal-title":"J Hosp Infect"},{"key":"894_CR15","unstructured":"Escobar GJ, Baker M, Li SX, Xie Y, Kipnis P. Clinical and Economic Burden of Recurrent Clostridium difficile Infections\u2014a 10-Year Retrospective Large Database Analysis. ICAAC Washington DC September 5\u20139, 2014 Abstract K-362 Available from: http:\/\/www.icaaconline.com\/php\/icaac2014abstracts\/data\/papers\/2014\/K-362.htm . Accessed June 2015."},{"key":"894_CR16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s15010-015-0810-x","volume":"43","author":"SM Heimann","year":"2015","unstructured":"Heimann SM, Vehreschild JJ, Cornely OA, Wisplinghoff H, Hallek M, Goldbrunner R, et al. Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. Infection. 2015;43:707\u201314.","journal-title":"Infection"},{"key":"894_CR17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","volume":"12","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12:281\u20139.","journal-title":"Lancet Infect Dis"},{"key":"894_CR18","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1093\/jac\/dku257","volume":"69","author":"D Nathwani","year":"2014","unstructured":"Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IA. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother. 2014;69:2901\u201312.","journal-title":"J Antimicrob Chemother"},{"key":"894_CR19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.36469\/9903","volume":"2","author":"A Engen van","year":"2015","unstructured":"van Engen A, Casamayor M, Loftus F, Coen M, Garnham A, Watt M, Lacey L. Economic evaluation of fidaxomicin for the treatment of Clostridium difficile infection (C. difficile-associated diarrhoea) in Ireland. JHEOR. 2015;2:192\u2013206.","journal-title":"JHEOR"},{"key":"894_CR20","doi-asserted-by":"crossref","unstructured":"Kuijper EJ, Coignard B, T\u00fcll P, the ESCMID Study Group for Clostridium difficile (ESGCD) and EU Member States and the European Centre for Disease Prevention and Control (ECDC). Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12:2\u201318.","DOI":"10.1111\/j.1469-0691.2006.01580.x"},{"key":"894_CR21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1055\/s-0034-1398803","volume":"53","author":"RF Grube","year":"2015","unstructured":"Grube RF, Heinlein W, Scheffer H, Rathmayer M, Schepp W, Lohse AW, et al. Economic burden of Clostridium difficile enterocolitis in German hospitals based on routine DRG data. Z Gastroenterol. 2015;53:391\u20137.","journal-title":"Z Gastroenterol"},{"key":"894_CR22","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1086\/596703","volume":"48","author":"D Gravel","year":"2009","unstructured":"Gravel D, Miller M, Simor A, Taylor G, Gardam M, McGeer A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis. 2009;48:568\u201376.","journal-title":"Clin Infect Dis"},{"key":"894_CR23","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1378\/chest.07-0202","volume":"132","author":"C Kenneally","year":"2007","unstructured":"Kenneally C, Rosini JM, Skrupky LP, Doherty JA, Hollands JM, Martinez E, et al. Analysis of 30-day mortality for Clostridium difficile-associated disease in the ICU setting. Chest. 2007;132:418\u201324.","journal-title":"Chest"},{"key":"894_CR24","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa051639","volume":"353","author":"VG Loo","year":"2005","unstructured":"Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442\u20139.","journal-title":"N Engl J Med"},{"key":"894_CR25","unstructured":"Lauer Fischer. Available from: www.lauer-fischer.de\/LF\/Seiten\/Verwaltung\/Kundencenter.aspx . Accessed Aug 2014."},{"key":"894_CR26","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.14309\/00000434-201310001-00575","volume":"108","author":"S Patel","year":"2013","unstructured":"Patel S, Kelly C, Colombel J-F, Atreja A. Comparative cost analysis of fecal microbiota transplant and antibiotic treatment for recurrent Clostridium difficile infection. Am J Gastroenterol. 2013;108:S169.","journal-title":"Am J Gastroenterol"},{"key":"894_CR27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/BOT.0b013e31816b7880","volume":"22","author":"GP Slobogean","year":"2008","unstructured":"Slobogean GP, Kennedy SA, Davidson D, O\u2019Brien PJ. Single-versus multiple-dose antibiotic prophylaxis in the surgical treatment of closed fractures: a meta-analysis. J Orthop Trauma. 2008;22:264\u20139.","journal-title":"J Orthop Trauma"},{"key":"894_CR28","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. Available from: https:\/\/www.nice.org.uk\/article\/pmg9\/resources\/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf . Accessed Sep 2015."},{"key":"894_CR29","doi-asserted-by":"crossref","unstructured":"Schwander B. The future health economic potential of next generation artificial vision devices for treating blindness in Germany: an early cost-utility assessment. Poster PSS35 presented at 17th Annual ISPOR European Congress, Amsterdam, The Netherlands; 11th November 2014.","DOI":"10.1016\/j.jval.2014.08.2133"},{"key":"894_CR30","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1093\/cid\/cis499","volume":"55","author":"DW Crook","year":"2012","unstructured":"Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis. 2012;55:S93\u2013103.","journal-title":"Clin Infect Dis"},{"key":"894_CR31","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ajic.2014.11.004","volume":"43","author":"T Chopra","year":"2015","unstructured":"Chopra T, Neelakanta A, Dombeck C, Awali RA, Sharma S, Kaye KS, Patel P. Burden of Clostridium difficile infection on hospital readmissions and its potential impact under the Hospital Readmission Reduction Program. Am J Infect Control. 2015;43:314\u20137.","journal-title":"Am J Infect Control"},{"key":"894_CR32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2710.2000.00266.x","volume":"25","author":"FA Al-Eidan","year":"2000","unstructured":"Al-Eidan FA, McElnay JC, Scott MG, Kearney MP. Clostridium difficile-associated diarrhoea in hospitalised patients. J Clin Pharmacy Ther. 2000;25:101\u20139.","journal-title":"J Clin Pharmacy Ther"},{"key":"894_CR33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/IPC.0000000000000181","volume":"23","author":"E Eiland","year":"2015","unstructured":"Eiland E, Sawyer AJ, Massie NL. Fidaxomicin use and clinical outcomes for clostridium difficile\u2013associated diarrhea. Infect Dis Clin Pract. 2015;23:32\u20135.","journal-title":"Infect Dis Clin Pract."},{"key":"894_CR34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jval.2012.11.004","volume":"16","author":"PM Stranges","year":"2013","unstructured":"Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health. 2013;16:297\u2013304.","journal-title":"Value Health"},{"key":"894_CR35","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s10096-015-2472-0","volume":"34","author":"C Rubio-Terr\u00e9s","year":"2015","unstructured":"Rubio-Terr\u00e9s C, Cobo Reinoso J, Grau Cerrato S, Mensa Pueyo J, Salavert Llet\u00ed M, Toledo A, et al. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain. Eur J Clin Microbiol Infect Dis. 2015;34:2213\u201323.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"894_CR36","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cmi.2014.08.017","volume":"21","author":"MA Olsen","year":"2015","unstructured":"Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect. 2015;21:164\u201370.","journal-title":"Clin Microbiol Infect"},{"key":"894_CR37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/1469-0691.12046","volume":"18","author":"CP Kelly","year":"2012","unstructured":"Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18:21\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"894_CR38","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/jac\/dku261","volume":"69","author":"OA Cornely","year":"2014","unstructured":"Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother. 2014;69:2892\u2013900.","journal-title":"J Antimicrob Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-016-0894-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15010-016-0894-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-016-0894-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-016-0894-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T06:40:36Z","timestamp":1600411236000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-016-0894-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,9]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["894"],"URL":"https:\/\/doi.org\/10.1007\/s15010-016-0894-y","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,9]]}}}